{"id":54889,"date":"2023-03-16T07:03:13","date_gmt":"2023-03-16T06:03:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/"},"modified":"2023-03-16T07:03:13","modified_gmt":"2023-03-16T06:03:13","slug":"benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/","title":{"rendered":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>A year of strong operational progress with focused investment to drive future growth<\/i>\n<\/p>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory\u00a0News:\n<\/p>\n<p>\nBenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d or the \u201cGroup\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022.\n<\/p>\n<p>\n<b>Joanna Shields, Chief Executive Officer of BenevolentAI, said:<\/b>\n<\/p>\n<p>\n<i>\u201cWith the world\u2019s attention on AI applications that deliver real-world impact, our progress in 2022 strongly positions BenevolentAI to capitalise on this moment. Our AI platform is proven to enhance drug discovery, as demonstrated by our growing pipeline and successful collaboration with AstraZeneca. Notable clinical and commercial milestones during the period include completing recruitment for our Phase II trial for BEN-2293, submitting the CTA for BEN-8744 and delivering an additional three novel targets to AstraZeneca\u2019s portfolio.\u201d<\/i>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Operational highlights (including post period)<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Delivered performance enhancements across the Benevolent Platform\u2122<\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIntroduced the next generation Knowledge Graph, powered by advanced natural language processing (NLP) to enable more precise predictions\n<\/li>\n<li>\nExpanded Target ID tools to discover targets best prosecuted via alternative modalities\n<\/li>\n<li>\nSubstantially improved our suite of target identification tools; introduced sophisticated large language models to predict novel therapeutic drug targets from scientific literature\n<\/li>\n<li>\nLaunched a product for target progressibility assessments, enhancing R&amp;D decisions across factors like druggability, selectivity and competitor and patent landscapes\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Achieved sustained progress in our platform-generated clinical and pre-clinical pipeline<\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<p>\nBEN-2293\n<\/p>\n<ul class=\"bwlistsquare\">\n<li>\n<p>\nA topical potentially best-in-class PanTrk inhibitor in development to relieve inflammation and rapidly resolve the itch in patients with atopic dermatitis (AD)\n<\/p>\n<\/li>\n<li>\n<p>\nCompleted a Phase IIa study and expect top-line data by the end of March 2023\n<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>\nBEN-8744\n<\/p>\n<ul class=\"bwlistsquare\">\n<li>\n<p>\nAn oral peripherally-restricted small molecule PDE10 inhibitor under development as a first-in-class treatment for ulcerative colitis (UC) and with potential for other indications within inflammatory bowel diseases\n<\/p>\n<\/li>\n<li>\n<p>\nSubmitted a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in December 2022, and expect to initiate a Phase I clinical trial in H1 2023\n<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>\nBEN-28010\n<\/p>\n<ul class=\"bwlistsquare\">\n<li>\n<p>\nAn orally administered asset under development as a best-in-class treatment for glioblastoma multiforme (GBM)\n<\/p>\n<\/li>\n<li>\n<p>\nDeclared as a clinical candidate in July 2022, with preparation for IND-enabling studies ongoing\n<\/p>\n<\/li>\n<li>\n<p>\nThe asset could be ready for Phase I studies in 2024\n<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Grew our pre-clinical pipeline<\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<p>\nTransitioned three assets into lead optimisation\n<\/p>\n<\/li>\n<li>\n<p>\nGenerated four new drug programmes using the Benevolent Platform<sup>TM<\/sup>\n<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Delivered strong performance in commercial Target ID collaboration with AstraZeneca<\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\nDelivered three additional novel targets discovered using the Benevolent Platform\u2122 to AstraZeneca\u2019s drug discovery portfolio\n<\/li>\n<li>\nA total of five novel targets, two for chronic kidney disease (CKD) and three for idiopathic pulmonary fibrosis (IPF), have now been validated and selected for portfolio-entry by AstraZeneca\n<\/li>\n<li>\nEach novel target selected by AstraZeneca has the potential to generate significant milestones and royalties for BenevolentAI\n<\/li>\n<li>\nIn January 2022, the collaboration was extended for a further 3 years to include heart failure (HF) and systemic lupus erythematosus (SLE)\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Eli Lilly achieved full FDA approval for baricitinib in May 2022. BenevolentAI scientists first identified baricitinib as a COVID-19 treatment using the Benevolent Platform\u2122 in January 2020<\/b>\n<\/li>\n<li>\n<p>\n<b>Initiated a non-commercial collaboration with the Drugs for Neglected Disease initiative (DND<i>i<\/i>) and with Stanford University-based Helix Group<\/b>\n<\/p>\n<\/li>\n<li>\n<p>\n<b>Made new appointments to strengthen the experience on BenevolentAI\u2019s Board<\/b>\n<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIn April 2022, Dr Oliver Brandicourt, former CEO of Sanofi and Jean Raby, Partner at Astorg, appointed to the Board as a part of the Business Combination.\n<\/li>\n<li>\nGlobal ethics and governance expert, Dr Susan Liautaud joined the Board in June 2022\n<\/li>\n<li>\nKenneth Mulvany and Michael Brennan, two of the Company\u2019s co-founders, stepped down from their positions as Non-Executive Directors.\n<\/li>\n<li>\nPost period, in January 2023, the Board appointed Jean Raby to an additional new role as Senior Independent Non-Executive Director and Dr John Orloff to an additional new role as Workforce Non-Executive Director.\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b><span class=\"bwuline\">Financial highlights<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nRevenue increased to \u00a310.6 million (2021: \u00a34.6m), primarily reflecting increased revenues from the AstraZeneca collaboration\n<\/li>\n<li>\n\u00a312.1 million R&amp;D tax credits received in the period\n<\/li>\n<li>\nCompleted business combination and listing on Euronext Amsterdam in April 2022 raising \u00a3186.8 million (\u20ac225 million) gross proceeds.\n<\/li>\n<li>\nNet cash, cash equivalents and short-term deposits position of \u00a3130.2 million as of 31 December 2022 at the top end of market guidance (2021: \u00a340.6m)\n<\/li>\n<li>\nMaintained cash runway to Q4 2024, despite inflationary headwinds\n<\/li>\n<\/ul>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>Twelve months ended<\/b>\n<\/p>\n<p class=\"bwalignr bwcellpmargin\">\n<b>31 December<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u00a3&#8217;000<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u00a3&#8217;000<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>% Change<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10,560\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,625\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n128%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNormalised research and development spend\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(71,884)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(56,916)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n26%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNormalised administrative expenses\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(33,440)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(55,510)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-40%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Normalised operating loss<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(94,598)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(107,711)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-12%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNormalised basic and diluted EPS, expressed in pence\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(72.6p)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(104.6p)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n-31%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Reported operating loss<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(197,034)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(121,322)<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n62%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nReported basic and diluted EPS, expressed in pence\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(150.2p)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(119.8p)\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n25%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Cash, cash equivalents and short-term deposits<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n130,182\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n40,553\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwpadl0 bwpadr0 bwalignr\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n221%\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Analyst and Investor briefing<\/b>\n<\/p>\n<p>\nManagement will host an analyst briefing at 9.30 am this morning, 16 March 2023, at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom). To register your interest in attending either in person or virtually, analysts should contact FTI Consulting at <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#66;e&#x6e;&#101;v&#x6f;&#108;e&#x6e;&#116;A&#x49;&#64;f&#x74;&#105;c&#x6f;&#110;s&#x75;&#108;t&#x69;&#110;g&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#66;&#x65;&#x6e;&#101;&#x76;&#x6f;l&#x65;&#x6e;t&#65;&#x49;&#64;&#102;&#x74;i&#99;&#x6f;n&#115;&#x75;l&#116;&#x69;&#x6e;&#103;&#x2e;&#x63;&#111;&#x6d;<\/a>.\n<\/p>\n<p>\nA recording of the webcast will be made available in the investor section of the Company\u2019s website shortly afterwards.\n<\/p>\n<p>\n<b>About BenevolentAI<\/b>\n<\/p>\n<p>\nBenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform\u2122 powers the Company\u2019s in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.\n<\/p>\n<p>\n<b>Forward-looking Statements<\/b>\n<\/p>\n<p>\n<i>This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as &#8220;plans&#8221;, &#8220;targets&#8221;, &#8220;aims&#8221;, &#8220;believes&#8221;, &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;should&#8221; and similar expressions. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; economic outlook and industry trends; developments in BenevolentAI\u2019s markets; the impact of regulatory initiatives; and\/or the strength of BenevolentAI\u2019s competitors. These forward-looking statements reflect, at the time made, BenevolentAI\u2019s beliefs, intentions and current targets\/aims. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this release are based upon various assumptions based on, without limitation, management&#8217;s examination of historical operating trends, data contained in BenevolentAI\u2019s records, and third-party data. Although BenevolentAI believes these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond BenevolentAI\u2019s control. Forward-looking statements are not guarantees of future performance, and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of BenevolentAI or the industry to differ materially from those results expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. No representation or warranty is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.<\/i>\n<\/p>\n<p>\n<b>CHIEF EXECUTIVE\u2019S STATEMENT<\/b>\n<\/p>\n<p>\nI joined BenevolentAI as Chief Executive Officer nearly five years ago with a mission to align emerging technologies with science in a bold new way. Today, our ground-breaking AI platform is helping to drive a transformation in drug discovery by empowering scientists to uncover novel targets across many therapeutic areas for different modalities.\n<\/p>\n<p>\nOur progress in 2022 has solidified our leadership in the sector as we continued to advance our in-house pipeline and enhance our AI drug discovery platform, the Benevolent Platform\u2122. Commercially, we delivered solid performance in our highly productive collaboration with AstraZeneca, an important revenue driver for the Company, which provides strong scientific and commercial validation of our approach. During the period, AstraZeneca selected three additional novel targets for its portfolio, bringing the total to five novel targets selected to date, and extended the collaboration agreement for a further three years and in two new disease areas. This expansion of our collaboration led to a significant cash investment by AstraZeneca into the business as part of the Business Combination.\n<\/p>\n<p>\n<b>Discovery and development portfolio<\/b>\n<\/p>\n<p>\nAt BenevolentAI, our AI platform enables scientists to unravel the biological mechanisms underlying complex multifactorial diseases. Using our platform, we have generated a portfolio of 15 named drug programmes and more than ten exploratory programmes, representing a healthy balance of potentially first-in-class and best-in-class assets. This includes BEN-2293, which we are currently progressing through a Phase Ib\/IIa clinical study as a treatment for mild and moderate atopic dermatitis, with results expected in the first quarter of 2023. We filed a clinical trial application (CTA) in 2022 for our next most advanced programme, BEN-8744, for ulcerative colitis, with the objective to complete the Phase I clinical study by H1 2024 before initiating a Phase II study. Whilst the Benevolent Platform\u2122 is disease-agnostic, with the unique ability to rapidly identify novel targets in any disease area, going forward, we will focus our internal development pipeline on three core strategic areas: immunology, neurology and oncology, as announced in September 2022. We look to co-develop or out-license the programmes that are outside these therapy areas.\n<\/p>\n<p>\n<b>Product and technology<\/b>\n<\/p>\n<p>\nThroughout the year, we delivered performance enhancements to our world-leading AI drug discovery platform. We enhanced our data foundations by launching our next-generation Knowledge Graph, which is powered by advanced natural language processing (NLP) to enable more precise target predictions. We also substantially improved our suite of target identification tools, allowing scientists to discover targets best prosecuted via alternative modalities, and introduced sophisticated large language models (LLM) to predict novel therapeutic drug targets from scientific literature. Finally, we improved R&amp;D decisions by launching a powerful new tool that enables scientists to make target progressibility assessments based on factors like druggability, selectivity and competitor and patent landscapes.\n<\/p>\n<p>\nThese improvements to our transformative, scalable technology infrastructure have played a pivotal role in delivering key milestones in 2022 through our in-house pipeline and our successful collaboration with AstraZeneca.\n<\/p>\n<p>\n<b>Nurturing continuous innovation<\/b>\n<\/p>\n<p>\nInnovation is at the centre of everything we do, and 2022 reinforced our commitment to creating the conditions for innovation to flourish at BenevolentAI. Building on the legacy of our monthly \u2018Challenge Days\u2019 \u2013 set up during the pandemic \u2013 we brought our entire team together for Innovation Week 2022 hosted at our London headquarters for an intensive five days of cross-functional collaboration, which resulted in significant product enhancements, new development projects and enriched team cohesion.\n<\/p>\n<p>\nOur collaborations with academic innovators further multiply our opportunities for impact. In the first half of 2022, we initiated phase two of our AI research partnership with the Stanford University-based Helix Group, which focuses on discovering more effective methods to extract knowledge from biological and clinical information. Our innovation pipeline feeds into our intellectual property portfolio, including 91 tech-related applications and 122 drug discovery patent applications, representing an important strategic asset for BenevolentAI.\n<\/p>\n<p>\n<b>Impact<\/b>\n<\/p>\n<p>\nBenevolentAI is a purposeful company, and we believe it is important to amplify the impact of our platform and put our technology to good use for wider societal benefit. While our core strategy is to discover novel targets and develop better treatments through our in-house pipeline and partnerships, our non-commercial deployments compliment this core mission in the interest of the global good. One of the most visible applications of our approach was in support of the global campaign against COVID-19. This year we received further validation of the results of AI-enabled research, Baricitinib, the drug identified by BenevolentAI as a treatment for COVID-19 in January 2020, was fully approved by the US Food and Drug Administration (FDA). Baricitinib has been a mainstay of treatment in hospitals globally since being approved for emergency use by the FDA in November 2020, and its success in saving the lives of critically ill COVID-19 patients is a testament to the power of our platform and its potential to enhance and accelerate life-saving research.\n<\/p>\n<p>\nFurther underscoring our commitment to using our platform for broader societal benefit, we signed a new not-for-profit partnership with the Drugs for Neglected Diseases initiative (DNDi) in 2022. The partnership aims to identify targets and approved drugs that could be used to treat dengue fever, a climate-sensitive neglected disease representing one of the top ten threats to global public health worldwide.\n<\/p>\n<p>\n<b>Outlook<\/b>\n<\/p>\n<p>\nCompleting our business combination and successfully listing on Euronext Amsterdam in April 2022 was a testament to the strength of our business and growth story. As a result, we closed 2022 in a strong financial position, with a cash runway to Q4 2024 and sufficient capital to support our pipeline and strategy to drive long-term value creation.\n<\/p>\n<p>\nWe have several value inflection points both in the near and medium term. We expect top-line results of the Phase IIa clinical study for BEN-2293 in Q1 2023, and subject to results we will focus on out-licensing of BEN-2293 for atopic dermatitis post-Phase IIa data and initiate a Phase I study for BEN-8744 for ulcerative colitis in H1 2023. We also plan on delivering one to two CTA or IND-stage drug candidates. We expect to commence IND-enabling studies for at least one additional asset whilst transitioning three projects into lead optimisation, initiating four new drug discovery programmes. We also aim at signing an additional collaboration in the year ahead.\n<\/p>\n<p>\n2023 has the potential to be a breakthrough year for BenevolentAI. With the world\u2019s attention on AI applications that deliver real-world impact, we are strongly positioned to capitalise on this moment. With our substantial portfolio of platform-generated drugs, our work with big pharma and research collaborators, and our continued investment in state-of-the-art technology, we are showing every day how AI can be used to unlock the next wave of biopharma innovation.\n<\/p>\n<p>\nWe believe our leading platform will empower scientists to uncover novel treatments faster and with a higher probability of clinical success. Ultimately, our ambition is to facilitate the scaled development of new, more effective treatments for the patients who need them. I am confident in our ability to deliver on this mission.\n<\/p>\n<p>\n<b>Joanna Shields<\/b>\n<\/p>\n<p>\nChief Executive Officer\n<\/p>\n<p>\n<b>FINANCIAL REVIEW<\/b>\n<\/p>\n<p>\nWe have delivered a strong operational performance, achieving the majority of our strategic objectives within budget and ending the year with cash at the top end of our stated guidance. With the business combination completed (notes 2.4 and 4 of the financial statements) and the Company listed on Euronext Amsterdam in April 2022, we are in a strong position to deliver on our stated objectives and to create shareholder value.\n<\/p>\n<p>\nIn 2023 we look forward to the results of BEN-2293 within atopic dermatitis and the upcoming Phase I study of BEN-8744 in ulcerative colitis while also continuing to drive progress across our broader development pipeline. We will also continue to invest and drive innovation across our Product &amp; Technology stack in a targeted manner to retain our differentiated position. Against a macroeconomic backdrop of rising inflation and increasing financial pressures, we have reviewed and refined our spend profile to keep to our stated cash runway target of Q4 2024 whilst still delivering on the predefined objectives as at our interim results.\n<\/p>\n<p>\n<b>Revenues<\/b>\n<\/p>\n<p>\nAt BenevolentAI, we aim to monetise our platform through commercial collaborations and through developing our pipeline of wholly-owned assets with the aim of out-licensing, co-developing\/co-commercialising or, potentially, eventually, commercialising in-house.\n<\/p>\n<p>\nThe Group\u2019s revenues increased by \u00a36.0 million to \u00a310.6 million (2021: \u00a34.6 million), primarily reflecting increased revenues from the AstraZeneca collaboration and the majority of this increase reflecting a second AI-enabled drug discovery collaboration that started in January 2022, combined with revenue from a one-year extension to the initial collaboration that began in late 2021. We also recognised three milestone payments in 2022 as AstraZeneca selected three additional novel targets in chronic kidney disease (one target) and idiopathic pulmonary fibrosis (two targets).\n<\/p>\n<p>\n<b>Alternative performance measures and normalised presentation<\/b>\n<\/p>\n<p>\nThe normalised presentation of the Group performance can be found in the Consolidated statement of comprehensive income and explained further in note 2.4 of the financial statements.\n<\/p>\n<p>\n<b>Research and development (R&amp;D) expenses<\/b>\n<\/p>\n<p>\nThe Group\u2019s investment in R&amp;D is vital to its long-term growth strategy. Our spend can be split across two verticals: 1) Product &amp; Technology, which helps scientists understand complex biology, predict targets and help design and develop drugs for disease and 2) Drug Discovery, where our team of scientists then use our technology stack to pick novel targets for disease before developing drugs for these targets. The output of this symbiotic relationship is in the form of collaborations, such as with AstraZeneca and our pipeline of now 15 named programmes. The normalised presentation of the Group performance can be found in the Consolidated statement of comprehensive income and explained further in note 2.4 of the financial statements.\n<\/p>\n<p>\nNormalised product and technology spend, excluding share-based payments, for 2022 increased to \u00a321.9 million (2021: \u00a320.0 million) due to increased staff-related costs to support the continued expansion of the Benevolent Platform\u2122. Reported product and technology spend in 2022 decreased to \u00a324.3 million from \u00a325.1 million in 2021 reflecting lower share-based payment expenses.\n<\/p>\n<p>\nNormalised drug discovery spend, excluding share-based payments, for 2022 increased to \u00a343.2 million (2021: \u00a327.1 million). Reported drug discovery spend for 2022 increased to \u00a347.6 million (2021: \u00a331.8 million). The normalised increase was driven by advancing the BenevolentAI pipeline into later stages of development, particularly BEN-2293 and its progression through an adaptive Phase I\/II clinical study, alongside BEN-8744 CTA filing enablement in December 2022. We also added a net 4 named programmes into our pipeline during the year.\n<\/p>\n<p>\n<b>General and administrative costs<\/b>\n<\/p>\n<p>\nWith the business listing in 2022, we have made targeted investments in our operational structures to support our status as a listed business, particularly across finance, compliance, legal and risk activities. The Group continues to make material investments in building and protecting its IP portfolio (consisting of patents, trade secrets, copyright and trademarks). Finally, post-year end, we have also increased investment in our business development capabilities as our pipeline matures and reaches key value inflection points. Normalised business operations spend, excluding employee-related share-based payments, for 2022 has increased to \u00a316.5 million (2021: \u00a313.9 million). Reported business operations spend, excluding employee-related share-based payments, for 2022 has increased to \u00a3115.0 million from \u00a327.6 million in 2021. The normalised increase reflects those additional costs related to listing readiness and operating as a public company highlighted above. These costs are expected to stay at these levels given the enhanced level of compliance and reporting obligations and previously discussed investments.\n<\/p>\n<p>\n<b>Share-based payments (SBPs)<\/b>\n<\/p>\n<p>\nNormalised SBP spend for 2022 has decreased to \u00a323.7 million (2021: \u00a351.4 million). Reported SBP spend for 2022 has decreased to \u00a327.6 million (2021: \u00a351.4 million). The normalised change is predominantly driven by the recognition of vested options under the legacy BEIS share incentive scheme for 2022 of \u00a322.4 million (2021: \u00a351.4 million). This includes a \u00a36.5 million credit in relation to employer-related taxes in 2022 (2021: \u00a312.4 million charge on initial recognition). In 2022, the Group initiated a new LTIP for which a \u00a31.3 million charge has been recognised and which is expected to incur an ongoing SBP charge, inclusive of employer-related taxes, of between \u00a36.2 million and \u00a39.0 million based upon the share price as at the end of December.\n<\/p>\n<p>\nThe fair value charging methodology for the legacy BEIS plan has been re-assessed to reflect a now-known \u201cpoint of exit\u201d and a graded vesting profile. This correction has resulted in an additional \u00a321.2 million SBP charge and restatement to 2021 profit and loss, with a corresponding credit to the share-based payment reserve and employer-related tax provision on 31 December 2021.\n<\/p>\n<p>\n<b>Operating loss<\/b>\n<\/p>\n<p>\nNormalised operating loss for 2022 decreased to \u00a394.6 million (2021: \u00a3107.7 million). The reported operating loss for 2022 increased to \u00a3197.0 million (2021: \u00a3121.3 million) primarily due to the costs arising from the business combination, which are not expected to continue in 2023.\n<\/p>\n<p>\n<b>Finance income<\/b>\n<\/p>\n<p>\nFinance income for 2022 has increased to \u00a319.3 million (2021: \u00a356,000). This is predominantly driven by the fair value revaluation of the warrant liabilities acquired through the Transaction, reflecting an increase in their value as of 31 December 2022 compared to the Transaction date of \u00a317.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Enquiries:<\/span><\/b>\n<\/p>\n<p>\n<b>B<\/b><b>enevolentAI:<\/b><br \/>Nick Keher, Chief Financial Officer<br \/>\n<br \/>T: +44(0) 203 781 9360\n<\/p>\n<p>\n<b>Investors:<\/b><br \/>Fleur Wood \u2013 VP Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#111;&#58;&#102;&#108;eur&#x2e;&#x77;&#x6f;&#x6f;&#x64;&#x40;&#98;&#101;&#110;evo&#x6c;&#x65;&#x6e;&#x74;&#x2e;&#x61;&#105;\" rel=\"nofollow noopener\" shape=\"rect\">&#x66;&#108;&#101;u&#x72;&#x2e;&#119;o&#x6f;&#x64;&#64;be&#x6e;&#101;&#118;o&#x6c;&#x65;&#110;t&#x2e;&#x61;&#105;<\/a><br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;&#116;o&#x3a;&#x69;&#x6e;&#118;&#101;st&#x6f;&#x72;&#x73;&#64;&#98;e&#x6e;&#x65;&#x76;&#111;&#108;&#101;n&#x74;&#x2e;&#x61;&#105;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#110;v&#x65;&#x73;&#116;o&#x72;&#115;&#64;&#x62;&#x65;&#110;e&#x76;&#111;l&#x65;&#x6e;&#116;&#46;&#x61;&#x69;<\/a><br \/>T: +44(0) 203 781 9360\n<\/p>\n<p>\n<b>Media:<\/b><br \/>Rajin Kang &#8211; VP Communications<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;r&#x61;&#x6a;&#105;n&#46;&#x6b;&#97;&#110;g&#x40;&#x62;&#101;n&#x65;&#x76;&#111;&#108;e&#x6e;&#x74;&#46;a&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">&#114;&#x61;&#x6a;&#105;&#x6e;&#x2e;&#107;&#x61;&#x6e;&#103;&#x40;&#x62;&#101;&#x6e;&#x65;&#118;&#x6f;&#x6c;&#101;&#x6e;&#x74;&#46;&#x61;&#x69;<\/a><br \/>T: +44(0) 203 781 9360\n<\/p>\n<p>\n<b>FTI Consulting:<\/b><br \/>Ben Atwell\/Simon Conway\/Victoria Foster Mitchell<br \/>\n<br \/>T: +44 203 727 1000<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#66;&#x65;&#x6e;&#101;&#x76;&#x6f;l&#101;&#x6e;t&#65;&#x49;&#x40;&#102;&#x74;&#x69;c&#111;&#x6e;s&#117;&#x6c;&#x74;&#105;&#x6e;&#x67;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x42;&#x65;&#110;&#101;&#118;o&#x6c;&#x65;&#x6e;&#116;&#65;I&#64;&#x66;&#x74;&#x69;&#99;&#111;n&#x73;&#x75;&#x6c;&#116;&#105;&#110;g&#x2e;&#x63;&#x6f;&#109;<\/a>\n<\/p>\n<p> <a href=\"http:\/\/www.businesswire.com\/news\/home\/20230315005956\/en\/BenevolentAI-Unaudited-Preliminary-Results-for-the-Year-Ended-31-December-2022\/?feedref=Zd8jjkgYuzBwDixoAdXmJgT1albrG1Eq4mAeVP392103_ypKzv-7ah0oHKWbnuHnevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxZM7XiMhduiSeKMTNDLRqI_doMC3CVAuyHo5cJ7XfDuvA==\"> Read full story here <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>A year of strong operational progress with focused investment to drive future growth LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory\u00a0News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d or the \u201cGroup\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022. Joanna Shields, Chief Executive Officer of BenevolentAI, said: &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54889","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"A year of strong operational progress with focused investment to drive future growth LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory\u00a0News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d or the \u201cGroup\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022. Joanna Shields, Chief Executive Officer of BenevolentAI, said: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T06:03:13+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022\",\"datePublished\":\"2023-03-16T06:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/\"},\"wordCount\":3306,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/\",\"name\":\"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-16T06:03:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend","og_description":"A year of strong operational progress with focused investment to drive future growth LONDON&#8211;(BUSINESS WIRE)&#8211;Regulatory\u00a0News: BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d or the \u201cGroup\u201d) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery and development company, announces its unaudited preliminary results for the year ended 31 December 2022. Joanna Shields, Chief Executive Officer of BenevolentAI, said: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-16T06:03:13+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022","datePublished":"2023-03-16T06:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/"},"wordCount":3306,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/","name":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-16T06:03:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-unaudited-preliminary-results-for-the-year-ended-31-december-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54889"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54889\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}